Sage Journals: Discover world-class research

Abstract

We previously reported that 3-hydroxyphthalic anhydride-modified human serum albumin (HP-HSA) as an anti-HIV microbicide could potently inhibit infection by a broad spectrum of HIV-1 strains; however, its mechanism of action is still elusive. Here, we aimed to identify the target(s) of HP-HSA. HIV-1 envelope glycoprotein (Env)-mediated cell–cell fusion assays were conducted using noninfectious CHO-WT cells or infectious HIV-1_IIIB-infected H9 cells as effector cells and MT-2 as target cells. The cell-to-cell transmission and single-round HIV-1 infection assays were performed by measuring luciferase activity. Binding of HP-HSA to CD4 or gp120 was determined by enzyme-linked immunosorbent assay (ELISA) and flow cytometry, while binding of HP-HSA to the coreceptor CXCR4 or CCR5 was detected by cell-based ELISA. HP-HSA strongly inhibited HIV-1 Env-mediated cell–cell fusion and blocked infection by HIV-1 pseudoviruses bearing Env of HIV-1_HXB2 (X4 strain) or HIV-1_SF162 (R5 strain). HP-HSA was also effective in blocking HIV-1_BaL transmission from infected to uninfected cells. HP-HSA could strongly bind to HIV-1 Env gp120 and cellular receptor CD4. These results suggest that HP-HSA inhibits HIV-1 entry into the target cell by interacting with viral Env gp120 and/or the cellular CD4 receptor, making it a promising microbicide candidate for preventing HIV-1 sexual transmission.

Get full access to this article

View all access options for this article.

References

Buckheit

Jr , Watson

, Morrow

et al. Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res, 2010; 85:142–158.

Friend

. Pharmaceutical development of microbicide drug products. Pharm Dev Technol, 2010; 15:562–581.

McElrath

, Ballweber

, Terker

et al. Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells. Antimicrob Agents Chemother, 2010; 54:763–772.

Olsen

, Easterhoff

, Dewhurst

. Advances in HIV microbicide development. Future Med Chem, 2011; 3:2101–2116.

Obiero

, Mwethera

, Wiysonge

. Topical microbicides for prevention of sexually transmitted infections. Cochrane Database Syst Rev, 2012; 6:CD007961.

, Qiu

, Lu

et al. 3-Hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate inhibits HIV infection by blocking viral entry. J Antimicrob Chemother, 2013; 68:573–576.

Wilen

, Tilton

, Doms

. Molecular mechanisms of HIV entry. Adv Exp Med Biol, 2012; 726:223–242.

Chan

, Kim

. HIV entry and its inhibition. Cell, 1998; 93:681–684.

Hsu

, Harouse

, Gettie

et al. Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. J Virol, 2003; 77:989–998.

10.

Chan

, Fass

, Berger

et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell, 1997; 89:263–273.

11.

, Kim

. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J Biomol Struct Dyn, 1997; 15:465–471.

12.

Jiang

, Lin

, Lu

. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein. J Virol, 1998; 72:10213–10217.

13.

, He

, Tan

et al. 3-Hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: A potential microbicide for preventing sexual transmission of HIV-1. Antimicrob Agents Chemother, 2010; 54:1700–1711.

14.

, Qiao

, Yang

et al. Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission. Retrovirology, 2010; 7:37.

15.

Jiang

, Lu

, Liu

et al. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother, 2004; 48:4349–4359.

16.

Jiang

, Debnath

. Development of HIV entry inhibitors targeted to the coiled coil regions of gp41. Biochem Biophys Res Commun, 2000; 269:641–646.

17.

Chou

, Hayball

. CalcuSyn: Windows software for dose effect analysis. Ferguson, MO 63135, USA: BIOSOFT, 1991.

18.

Demirkhanyan

, Marin

, Padilla-Parra

et al. Multifaceted mechanisms of HIV-1 entry inhibition by human alpha-defensin. J Biol Chem, 2012; 287:28821–28838.

19.

Geuenich

, Goffinet

, Venzke

et al. Aqueous extracts from peppermint, sage and lemon balm leaves display potent anti-HIV-1 activity by increasing the virion density. Retrovirology, 2008; 5:27.

20.

Neurath

, Jiang

, Strick

et al. Bovine β-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptors for HIV-1. Nature Med, 1996; 2:230–234.

21.

Neurath

, Strick

, Li

et al. Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect Dis, 2001; 1:17.

22.

VanCott

, Mascola

, Kaminski

et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol, 1997; 71:4319–4330.

23.

Zhou

, Swiderski

, Li

et al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res, 2009; 37:3094–3109.

24.

Zhao

, Lu

, Schols

et al. Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4. AIDS Res Hum Retroviruses, 2003; 19:947–955.

25.

Liu

, Zhao

, Jiang

. Determination of the HIV-1 gp41 postfusion conformation modeled by synthetic peptides: Applicable for identification of the HIV-1 fusion inhibitors. Peptide, 2003; 24:1303–1313.

26.

Jiang

, Lin

, Zhang

et al. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J Virol Methods, 1999; 80:85–96.

27.

Berger

. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. J Urol, 2011; 185:1729.

28.

Abdool

, Abdool Karim

, Frohlich

et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 2010; 329:1168–1174.

29.

McEnery

. Oral tenofovir arm of VOICE trial discontinued early. IAVI Rep, 2011; 15:21.

30.

Tachet

, Dulioust

, Salmon

et al. Detection and quantification of HIV-1 in semen: Identification of a subpopulation of men at high potential risk of viral sexual transmission. AIDS, 1999; 13:823–831.

31.

Kelly

, Shattock

. Specific microbicides in the prevention of HIV infection. J Intern Med, 2011; 270:509–519.

32.

Kaizu

, Weiler

, Weisgrau

et al. Repeated intravaginal inoculation with cell-associated simian immunodeficiency virus results in persistent infection of nonhuman primates. J Infect Dis, 2006; 194:912–916.

33.

Neurath

, Debnath

, Strick

et al. 3-Hydroxyphthaloyl-β-lactoglobulin: I. Optimization of production and comparison with other compounds considered for chemoprophylaxis of mucosally transmitted HIV. Antiv Chem Chemother, 1997; 8:53–61.

34.

Luckheeram

, Zhou

, Verma

et al. CD4(+)T cells: Differentiation and functions. Clin Dev Immunol, 2012; 2012:925135.

35.

Schwartz

. T cell anergy. Annu Rev Immunol, 2003; 21:305–334.

36.

Rusconi

, Moonis

, Merrill

et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother, 1996; 40:234–236.

37.

Parish

, Low

, Warren

et al. A polyanion binding site on the CD4 molecule. Proximity to the HIV-gp120 binding region. J Immunol, 1990; 145:1188–1195.

38.

Jansen

, Schols

, Pauwels

et al. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Mol Pharmacol, 1993; 44:1003–1007.

39.

Kuipers

, vd Berg

, Swart

et al. Mechanism of anti-HIV activity of succinylated human serum albumin. Biochem Pharmacol, 1999; 57:889–898.

40.

Vermeulen

, Meijer

, Over

et al. A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor. Antivir Ther, 2007; 12:273–278.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.19 MB

0.05 MB

0.08 MB

0.03 MB

3-Hydroxyphthalic Anhydride-Modified Human Serum Albumin as a Microbicide Candidate Against HIV Type 1 Entry by Targeting Both Viral Envelope Glycoprotein gp120 and Cellular Receptor CD4

Abstract

Get full access to this article

References

Supplementary Material